Brain pathway linked to clozapine-related weight gain in mice

At UT Southwestern Medical Center, female mice switched to a nutritionally matched diet containing clozapine began eating more, especially at night. Over 12 weeks, they gained fat, and researchers traced much of that response to an MC4R-Kir7.1 signaling pathway in the brain—a possible route to easing a metabolic side effect of a medicine used for treatment-resistant schizophrenia.

Chen Liu's team focused on MC4R neurons in the paraventricular hypothalamus, a brain region involved in appetite control. These neurons help suppress feeding. Kir7.1, a potassium channel in the same cells, acts like an electrical brake: when it opens, the neurons become less active and their appetite-suppressing signal weakens. In the mice, clozapine and risperidone suppressed this activity, while ziprasidone, which is less likely to cause weight gain, did not.

The researchers then tested ways to interrupt the circuit. Deleting Kir7.1 only from MC4R-expressing neurons markedly reduced clozapine-induced weight gain, without weakening clozapine's effect in a standard mouse test of antipsychotic activity. Setmelanotide, an MC4R-activating drug approved for certain rare genetic forms of obesity, reduced food intake and body weight in clozapine-treated mice. In mice that had already developed obesity, the experimental Kir7.1 blocker ML418 reduced eating, body weight and fat mass and improved glucose tolerance.

In practice, the immediate result is a clearer biological target, not a new prescription. For people who depend on clozapine, the potential benefit is a future add-on treatment that could reduce its metabolic burden while preserving its psychiatric effect—but only if the finding survives testing beyond mice. Setmelanotide was tested here in mice, and ML418 remains experimental.

The limits are built into the experiment. The study used female mice, and clozapine was incorporated into their diet to reproduce blood concentrations reported in patients. Liu also said the MC4R-Kir7.1 pathway is not the whole story: mice still gained weight with olanzapine, suggesting that antipsychotic drugs can reach the appetite-control system through different routes. A companion study led by Roger D. Cone at the University of Michigan added structural evidence for Kir7.1 as a regulator of feeding, but the combined work remains preclinical.